NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

Phase 2

Completed

Conditions: Lymphoma
T-Cell
Cutaneous

Interventions: Biological: LMB-2

First Posted Date: 2004-04-07

Last Posted Date: 2018-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00080535

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-05

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019071

Locations: 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States

Radiation Therapy in Treating Patients With Glioblastoma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-05

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00019058

Locations: 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Melanoma (Skin)
Kidney Cancer

First Posted Date: 2004-04-05

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020540

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Gemcitabine in Treating Children With Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: gemcitabine hydrochloride

First Posted Date: 2004-04-02

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00005577

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 20 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Phase 1

Conditions: Head and Neck Cancer

First Posted Date: 2004-03-31

Last Posted Date: 2013-09-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004097

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

First Posted Date: 2004-03-29

Last Posted Date: 2012-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00080353

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Lymphoma
Neutropenia
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cyclosporine
Drug: irinotecan hydrochloride
Drug: phenobarbital

First Posted Date: 2004-03-26

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002759

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)

Not Applicable

Active, not recruiting

Conditions: Prostate Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Medical Examination
Other: Screening Questionnaire Administration

First Posted Date: 2004-03-26

Last Posted Date: 2025-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 76685

Registration Number: NCT00002540

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Gender, Obesity, C-Reactive Protein, and Oxidative Stress

Not Applicable

Completed

Conditions: Cardiovascular Disease

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Vitamin C
Dietary Supplement: Vitamin E

First Posted Date: 2004-03-22

Last Posted Date: 2017-09-27

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 396

Registration Number: NCT00079963

Locations: 🇺🇸
University of California, Berkeley School of Public Health, Berkeley, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy